UnknownPhase 2/3

Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients

China30 participantsStarted 2024-03-01

Plain-language summary

The goal of this clinical trial is to learn if drug Faricimab works to treat nAMD, DME or RVO in adults. It will also learn about the safety of drug Faricimab. The main questions it aims to answer are: Does drug Faricimab can improve the best-corrected visual acuity of participants? What medical problems do participants have when inject drug Faricimab? Participants will inject drug Faricimab every month for 3 months. Visit the clinic once every 2 weeks for checkups.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Chinese patients aged 18 years or older and of any gender;
✓. Patients who have been diagnosed with nAMD, DME or RVO by OCT, FFA, ICGA or OCTA;
✓. Patients whose decision to receive treatment with faricimab was made prior to and independent of study participation;
✓. Patients who have received at least one treatment with faricimab during the course of the study;
✓. have signed an informed consent form.

Exclusion criteria

✕. Active ocular inflammation or suspected active ocular infection in either eye;
✕. Receipt of any other anti-VEGF therapy after faricimab;
✕. Patient is unable to provide clinical data (visual acuity and OCT images) within 2 weeks (14 days) prior to receiving the initial faricimab injection;
✕. Currently participating in any other clinical trial.

What they're measuring

Best Corrected Visual Acuity (BCVA)

Timeframe: through study completion, an average of 3 months.

Trial details

NCT IDNCT06572553

SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-08-31

Contact for this trial

Panpan Ye, doctor

+86 13806506267 yepanpan@zju.edu.cn

View on ClinicalTrials.gov More Age-Related Macular Degeneration trials